Preladenant is an investigational drug.
There have been 13 clinical trials for Preladenant.
The most recent clinical trial was a Phase 3 trial, which was initiated on July 14th 2010.
The most common disease conditions in clinical trials are Parkinson Disease, Movement Disorders, and Dyskinesias. The leading clinical trial sponsors are Merck Sharp & Dohme Corp., Oregon Health and Science University, and [disabled in preview].